Allogene Therapeutics (ALLO) News Today $1.44 +0.06 (+4.35%) Closing price 04:00 PM EasternExtended Trading$1.45 +0.01 (+0.69%) As of 06:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Relay Therapeutics (NASDAQ:RLAY) & Allogene Therapeutics (NASDAQ:ALLO) Financial SurveyApril 4 at 1:28 AM | americanbankingnews.comCAR-T Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and CompaniesMarch 26, 2025 | theglobeandmail.comQ1 EPS Forecast for Allogene Therapeutics Lifted by AnalystAllogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) - HC Wainwright upped their Q1 2025 earnings estimates for Allogene Therapeutics in a research report issued on Wednesday, March 19th. HC Wainwright analyst R. Burns now forecasts that the company will post earnings of ($0.27) per share forMarch 22, 2025 | marketbeat.comAllogene Therapeutics, Inc. (NASDAQ:ALLO) Shares Sold by Primecap Management Co. CAPrimecap Management Co. CA decreased its position in Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) by 13.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,927,340 shares of tMarch 21, 2025 | marketbeat.comHC Wainwright Has Lowered Expectations for Allogene Therapeutics (NASDAQ:ALLO) Stock PriceHC Wainwright dropped their target price on shares of Allogene Therapeutics from $9.00 to $8.00 and set a "buy" rating for the company in a research report on Wednesday.March 20, 2025 | marketbeat.comAllogene Therapeutics, Inc. (NASDAQ:ALLO) Sees Large Increase in Short InterestAllogene Therapeutics, Inc. (NASDAQ:ALLO - Get Free Report) was the target of a large increase in short interest during the month of February. As of February 28th, there was short interest totalling 39,100,000 shares, an increase of 16.2% from the February 13th total of 33,660,000 shares. Currently, 29.1% of the shares of the company are sold short. Based on an average daily trading volume, of 5,120,000 shares, the short-interest ratio is currently 7.6 days.March 20, 2025 | marketbeat.comAllogene Therapeutics price target lowered to $8 from $9 at H.C. WainwrightMarch 19, 2025 | markets.businessinsider.comBenjamin Machinas Beneski Sells 5,488 Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO) StockAllogene Therapeutics, Inc. (NASDAQ:ALLO - Get Free Report) SVP Benjamin Machinas Beneski sold 5,488 shares of the firm's stock in a transaction dated Friday, March 14th. The shares were sold at an average price of $1.98, for a total value of $10,866.24. Following the completion of the sale, the senior vice president now owns 218,507 shares of the company's stock, valued at approximately $432,643.86. This represents a 2.45 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.March 19, 2025 | marketbeat.comInsider Selling: Allogene Therapeutics, Inc. (NASDAQ:ALLO) CEO Sells 46,668 Shares of StockAllogene Therapeutics, Inc. (NASDAQ:ALLO - Get Free Report) CEO David D. Chang sold 46,668 shares of the business's stock in a transaction that occurred on Friday, March 14th. The shares were sold at an average price of $1.96, for a total value of $91,469.28. Following the completion of the transaction, the chief executive officer now directly owns 5,276,569 shares in the company, valued at approximately $10,342,075.24. The trade was a 0.88 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.March 19, 2025 | marketbeat.comAllogene Therapeutics, Inc. (NASDAQ:ALLO) SVP Sells $10,866.24 in StockMarch 19, 2025 | insidertrades.comAllogene Therapeutics management to meet virtually with TruistMarch 18, 2025 | markets.businessinsider.comAllogene Therapeutics (ALLO) Receives a Buy from OppenheimerMarch 18, 2025 | markets.businessinsider.comQ1 Earnings Estimate for ALLO Issued By William BlairAllogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) - Research analysts at William Blair issued their Q1 2026 earnings estimates for Allogene Therapeutics in a report released on Friday, March 14th. William Blair analyst S. Corwin anticipates that the company will post earnings of ($0.29) perMarch 17, 2025 | marketbeat.comCitizens Capital Markets Upgrades Allogene Therapeutics (ALLO)March 16, 2025 | msn.comRoyal Bank of Canada Reaffirms "Outperform" Rating for Allogene Therapeutics (NASDAQ:ALLO)Royal Bank of Canada reissued an "outperform" rating and issued a $10.00 target price on shares of Allogene Therapeutics in a report on Friday.March 15, 2025 | marketbeat.comCanaccord Genuity Group Reiterates Buy Rating for Allogene Therapeutics (NASDAQ:ALLO)Canaccord Genuity Group reiterated a "buy" rating and issued a $14.00 price target on shares of Allogene Therapeutics in a research note on Friday.March 15, 2025 | marketbeat.comAllogene Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues LagMarch 15, 2025 | finance.yahoo.comAllogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2024 Earnings Call TranscriptMarch 15, 2025 | msn.comAllogene Therapeutics, Inc. (NASDAQ:ALLO) Receives Consensus Recommendation of "Moderate Buy" from AnalystsShares of Allogene Therapeutics, Inc. (NASDAQ:ALLO - Get Free Report) have earned an average recommendation of "Moderate Buy" from the nine analysts that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation and eight havMarch 15, 2025 | marketbeat.comAllogene Therapeutics (NASDAQ:ALLO) Upgraded at Citizens JmpCitizens Jmp raised shares of Allogene Therapeutics from a "market perform" rating to an "outperform" rating and set a $5.00 price target for the company in a report on Friday.March 15, 2025 | marketbeat.comPiper Sandler Sticks to Their Buy Rating for Allogene Therapeutics (ALLO)March 14, 2025 | markets.businessinsider.comPiper Sandler Sticks to Their Buy Rating for Allogene Therapeutics (ALLO)March 14, 2025 | markets.businessinsider.comAllogene Therapeutics (NASDAQ:ALLO) Issues Earnings Results, Beats Expectations By $0.06 EPSAllogene Therapeutics (NASDAQ:ALLO - Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.34) by $0.06.March 14, 2025 | marketbeat.comAllogene upgraded to Outperform from Market Perform at Citizens JMPMarch 14, 2025 | markets.businessinsider.comTD Cowen Keeps Their Buy Rating on Allogene Therapeutics (ALLO)March 14, 2025 | markets.businessinsider.comAllogene Therapeutics, Inc. (ALLO) Q4 2024 Earnings Call TranscriptMarch 14, 2025 | seekingalpha.comAllogene Therapeutics reports Q4 EPS (28c), consensus (32c)March 13, 2025 | markets.businessinsider.comAllogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business UpdateMarch 13, 2025 | globenewswire.comAllogene Therapeutics (ALLO) to Release Quarterly Earnings on ThursdayAllogene Therapeutics (NASDAQ:ALLO) will be releasing earnings before the market opens on Thursday, March 13, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=264607)March 6, 2025 | marketbeat.comAre Allogeneic CAR-Ts the Future of LBCL Cancer Treatment? - Making Safe, Durable & Effective Universal Cell Therapies a RealityMarch 4, 2025 | msn.comAllogene Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business UpdateMarch 3, 2025 | globenewswire.comAllogene to invest $37.3M in expanded MRD assay pact with Foresight DiagnosticsFebruary 26, 2025 | markets.businessinsider.comAllogene: Assessing The Pipeline, Competitive Landscape, And OpportunitiesFebruary 26, 2025 | seekingalpha.comAllogene Therapeutics Announces Participation in March Investor ConferenceFebruary 26, 2025 | globenewswire.comAllogene Therapeutics Expands Strategic Partnership with Foresight Diagnostics to Advance Joint Development Activities Outside the US Across Europe, UK, Canada, and AustraliaFebruary 25, 2025 | globenewswire.comAllogene Short Interest Reportedly Near 5-Year Lows Amid Growing Retail Optimism: Analyst Sees CAR-T Therapy PromiseFebruary 24, 2025 | msn.comVontobel Holding Ltd. Boosts Stock Position in Allogene Therapeutics, Inc. (NASDAQ:ALLO)Vontobel Holding Ltd. boosted its holdings in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) by 788.4% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 195,457 shares of the company's stock after purchasFebruary 21, 2025 | marketbeat.comAllogene Therapeutics (NASDAQ:ALLO) Sees Unusually-High Trading Volume - Still a Buy?Allogene Therapeutics (NASDAQ:ALLO) Sees Unusually-High Trading Volume - Should You Buy?February 20, 2025 | marketbeat.comAllogene Therapeutics (NASDAQ:ALLO) Shares Gap Up - Should You Buy?Allogene Therapeutics (NASDAQ:ALLO) Shares Gap Up - Here's What HappenedFebruary 19, 2025 | marketbeat.comBaird ‘encouraged’ by Allogene CAR-T therapy updateFebruary 18, 2025 | markets.businessinsider.comTruist Financial Sticks to Its Buy Rating for Allogene Therapeutics (ALLO)February 18, 2025 | markets.businessinsider.comAllogene Therapeutics' SWOT analysis: CAR T pioneer's stock faces pivotal yearFebruary 17, 2025 | msn.comPartners Capital Investment Group LLP Trims Stake in Allogene Therapeutics, Inc. (NASDAQ:ALLO)Partners Capital Investment Group LLP reduced its position in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) by 63.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 93,248 sharesFebruary 17, 2025 | marketbeat.comAllogene Therapeutics (ALLO) Gets a Buy from Piper SandlerFebruary 14, 2025 | markets.businessinsider.comWilliam Blair Sticks to Its Buy Rating for Allogene Therapeutics (ALLO)February 14, 2025 | markets.businessinsider.comAllogene publishes data from ALPHA, ALPHA2 trials of cemacabtagene ansegedleucelFebruary 13, 2025 | markets.businessinsider.comAllogene reports promising results for CAR T therapy in lymphomaFebruary 13, 2025 | msn.comAllogene Therapeutics Announces Publication of Durable Response Data from Phase 1 ALPHA/ALPHA2 Trials of the Allogeneic CAR T Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma in the Journal of Clinical OncologyFebruary 13, 2025 | globenewswire.comAllogene stock plunges to 52-week low at $1.33 amid steep annual declineFebruary 12, 2025 | msn.comabrdn plc Buys Shares of 364,382 Allogene Therapeutics, Inc. (NASDAQ:ALLO)abrdn plc purchased a new position in Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 364,382 shares of the company's stock, valued at approximately $776,000. abrdn plc owned 0February 11, 2025 | marketbeat.com Remove Ads Get Allogene Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALLO and its competitors with MarketBeat's FREE daily newsletter. Email Address ALLO Media Mentions By Week ALLO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALLO News Sentiment▼0.000.61▲Average Medical News Sentiment ALLO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALLO Articles This Week▼24▲ALLO Articles Average Week Remove Ads Get Allogene Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALLO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies WVE News Today SPRY News Today CALT News Today EVO News Today DYN News Today ARDX News Today OCUL News Today AUPH News Today ADPT News Today IOVA News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALLO) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allogene Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Allogene Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ALLO Stock Free ALLO Stock Alerts